Havrix 720 Kinder (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix 720 Kinder is indicated for the prevention of hepatitis A infection in individuals for whom active immunisation is appropriate.

• Primary prophylaxis for hepatitis A in children and adolescents.
• Boosting immunity in persons previously vaccinated with another hepatitis A vaccine.
• Use in travelers to regions with intermediate or high hepatitis A endemicity.
• Administration as part of routine childhood immunisation schedules where recommended.
• Protection of individuals with chronic liver disease who are at increased risk of severe hepatitis A.
• May be co‑administered with other routine childhood vaccines according to local immunisation guidelines.

Following intramuscular injection, Havrix 720 Kinder can cause a range of adverse reactions, most of which are mild and resolve without medical intervention.

Common

• Pain, redness or swelling at the injection site.
• Low‑grade fever lasting 24–48 hours.
• Headache or mild fatigue.
• Transient nausea or abdominal discomfort.
• Mild muscle aches or joint pain.
• Temporary dizziness or feeling of weakness.
• Slight swelling of lymph nodes near the injection area.

Serious

• Severe allergic reaction (anaphylaxis) with difficulty breathing, hives or swelling of the face.
• Neurological events such as Guillain‑Barré syndrome, although rare.
• Persistent high fever (>39 °C) lasting more than 48 hours.
• Onset of rash or urticaria beyond the injection site.

Healthcare providers should evaluate individual health status before administering Havrix 720 Kinder and observe recommended safety measures.

• Confirm no history of severe allergic reaction to any component of the vaccine.
• Defer vaccination in persons with acute moderate or severe illness until recovery.
• Assess for immunocompromised conditions; vaccine may be less effective in such individuals.
• Consider postponement in pregnant women unless benefits outweigh potential risks.
• Review current medications that may affect immune response, such as immunosuppressants.
• Ensure proper intramuscular injection technique to minimize local reactions.
• Document lot number and administration date for pharmacovigilance.

Havrix 720 Kinder may interact with other agents that influence immune function or increase the risk of hypersensitivity.

Avoid

• Concurrent administration with live viral vaccines (e.g., measles, mumps, rubella) should be avoided within 4 weeks.
• Use with other inactivated hepatitis A vaccines or duplicate dosing.

Use with caution

• Immunosuppressive therapy (e.g., corticosteroids, biologics) may reduce vaccine efficacy; monitor antibody response.
• Antipyretics such as acetaminophen or ibuprofen can be given to manage post‑vaccination fever, but routine prophylactic use may blunt antibody production.
• Blood products or immunoglobulins given within 2 weeks before or after vaccination may interfere with immune response.
• Allergy testing agents containing gelatin or other excipients should be considered if the patient has known sensitivities.